Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91465 | 0.81 | CCNA2 (0.38) | LMNACCNA2CDK2CCNA1ALDH1A1 | |
| SCHEMBL10923148 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1732394 | 0.77 | CYP1A2 (0.36) | CCNA2CDK2CCNA1MEN1KMT2A | |
| SCHEMBL34473580 | 0.74 | LMNA (0.37) | LMNACCNA2CDK2CCNA1ALDH1A1 | |
| SCHEMBL30029657 | 0.74 | LMNA (0.50) | LMNAALDH1A1 | |
| SCHEMBL31211054 | 0.74 | LMNA (0.50) | LMNAALDH1A1 | |
| SCHEMBL68280 | 0.74 | LMNA (0.50) | LMNAALDH1A1 | |
| SCHEMBL24387277 | 0.71 | LMNA (0.32) | LMNACCNA2CDK2CCNA1 | |
| SCHEMBL29749852 | 0.71 | LMNA (0.32) | LMNACCNA2CDK2CCNA1 | |
| SCHEMBL84918 | 0.71 | CCNA2 (0.32) | LMNACCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011081310-A3 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME | 한국기초과학지원연구원 (KR) | 2011-10-27 | — | — | WO | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007035154-A1 | NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1633729-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | LMNA 4365/4885CCNA2 2580/4885CDK2 1971/4885 |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | CCR4, CCR1, CCR3 | LMNA 4864/4885CCNA2 2310/4885CDK2 646/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | LMNA 2861/4885CCNA2 385/4885CDK2 20/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | LMNA 3165/4885CCNA2 429/4885CDK2 34/4885 |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | LMNA 3767/4885CCNA2 3745/4885CDK2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.